Hemo Organic Ltd received a disclosure from Qmin Realities Private Limited regarding the acquisition of 17,00,000 equity shares, representing 24.76% of the company's voting capital. The transaction was executed through preferential allotment on September 25, 2026.

Qmin Realities Private Limited submitted the filing under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquirer is not part of the promoter or promoter group and has no persons acting in concert (PAC) with it. Prior to this acquisition, Qmin Realities held no shares in Hemo Organic.

Shareholding details

The acquisition significantly alters the shareholding pattern of Hemo Organic. The table below outlines the changes in holding before and after the transaction:

The total equity share capital of Hemo Organic increased from 34,65,900 shares to 68,65,900 shares following the allotment. The face value of each equity share remains ₹10.

What the numbers show

The preferential allotment nearly doubled Hemo Organic's total paid-up equity capital, expanding it from ₹3,46,59,000 to ₹6,86,59,000. This substantial increase in capital base indicates a significant infusion of funds into the company. Qmin Realities now holds a substantial minority stake, positioning it as a major non-promoter shareholder with significant influence potential, although it does not currently hold majority control.

Hemo Organic Limited reported a net loss of ₹7.42 lakh for the quarter ended June 30, 2026, as revenue from operations dropped to zero. The company recorded a total expense of ₹7.42 lakh for the period, resulting in a loss per share of ₹0.21. For the corresponding quarter in the previous year, the company had reported a revenue of ₹0.19 lakh and a net loss of ₹8.57 lakh.

The Board of Directors approved the unaudited standalone financial results for Q1FY26 at a meeting held on July 15, 2026. The results were prepared in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The statutory auditors conducted a limited review of the interim financial results.

MAAK & Associates, the statutory auditors, issued a qualified opinion in their review report. The firm stated that they were not provided with balance confirmations or other details for trade receivables and trade payables. Consequently, the auditors were unable to confirm the balance and nature of these transactions.

For the financial year ended March 31, 2026, Hemo Organic reported a total income of ₹93.10 lakh and a net loss of ₹77.81 lakh. The company's paid-up equity share capital remained unchanged at ₹346.59 lakh during the quarter. The basic and diluted earnings per share for the year stood at a loss of ₹2.24.

Financial Results for Q1FY26